NCT05623891

Safety Study of 177Lu-Anti-ED-B mAbs SPECT Imaging in Patients With ED-B Positive Solid Tumors

• Status: Unknown
• Phase: EARLY_Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Affiliated Hospital of Jiangnan University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled anti-ED-B mAbs SPECT imaging in patients with ED-B positive solid tumors.

Detailed description

After being fully informed about the study and potential risks, all patients giving written informed consent will be evaluated to determine eligibility for study entry. Patients will receive an injection of 177Lu-labeled anti-ED-B mAbs and will undergo SPECT/CT scanning to determine uptake of 177Lu-labeled anti-ED-B mAbs in tumor lesions and normal tissues and organs.

Conditions

• Solid Tumor, Adult

Interventions

Type	Name	Description
DRUG	177Lu-B5-IgG4	177Lu-B5-IgG4 injection followed by SPECT scan

Timeline

• Start date: 2022-12-01
• Primary completion: 2023-12-01
• Completion: 2023-12-01
• First posted: 2022-11-21
• Last updated: 2022-11-23

Locations

1 site across 1 country: China